Phase II Study of the Triple Combination Chemotherapy of SOXIRI (S‐1/Oxaliplatin/Irinotecan) in Patients with Unresectable Pancreatic Ductal Adenocarcinoma

LESSONS LEARNED. The triple combination chemotherapy of SOXIRI (S‐1/oxaliplatin/irinotecan) in patients with unresectable pancreatic ductal adenocarcinoma was an effective treatment that appeared to be better tolerated than the widely used FOLFIRINOX regimen. SOXIRI regimen may provide an alternativ...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:Oncologist
Main Authors: Akahori, Takahiro, Sho, Masayuki, Yanagimoto, Hiroaki, Satoi, Sohei, Nagai, Minako, Nishiwada, Satoshi, Nakagawa, Kenji, Nakamura, Kota, Yamamoto, Tomohisa, Hirooka, Satoshi, Yamaki, So, Ikeda, Naoya
Formato: Artigo
Idioma:Inglês
Publicado em: John Wiley & Sons, Inc. 2019
Assuntos:
Clinical Trial Results
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC6656520/
https://ncbi.nlm.nih.gov/pubmed/30679316
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1634/theoncologist.2018-0900
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados